Navigation Links
Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:10/1/2008

24, 30 and 36. Except for the month 12 and final month 36 looks when the database will be fully locked, interim evaluations will be based on unaudited data. The last patient was enrolled in this study at the end of February 2008.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.

For more information on Alimera Sciences, visit http://www.alimerasciences.com.


'/>"/>
SOURCE Alimera Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. BioView Reports Interim Results of Early Detection Lung Cancer Diagnostic Test
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Nutrition 21 Reports That National Toxicology Program Studies Support the Safety of Chromium Picolinate
8. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
9. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
10. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
11. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014 ... in Tokio veranstalteten ... firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. Die ... Überblick über die fortgeschrittenen klinischen Programme und ... Ziel der Tagung bestand darin, aktuelle Meldungen ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
(Date:7/11/2014)... 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. has announced ... for use in portable vaporizers, which contains CBD, ... in cannabis, cannabidiol offers consumers a THC-free product ... other vaporizer technology. Photo - ... 483 different compounds which are currently known, two ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... Md., Sept. 2 Celsion Corporation (Nasdaq: ... today that it has been awarded a competitive ... grant from the National Institutes of Health (NIH), ... Liposomes for Cancer".  This funding will support the ...
... Ascension Orthopedics, Inc., the world leader in ... the TITAN™ Modular Total Shoulder System. This newly ... solutions for shoulder arthroplasty with one implant system. ... was developed in collaboration with Joseph Abboud, M.D, ...
Cached Medicine Technology:Celsion Receives SBIR Grant To Expand Its Technology Platform 2Celsion Receives SBIR Grant To Expand Its Technology Platform 3Ascension Orthopedics Receives FDA Approval for TITAN™ Modular Total Shoulder System 2
(Date:7/13/2014)... editorial published today in The Lancet Neurology ... consideration the long term neurological problems that repeated ... most common form of sports-related traumatic brain injury ... may include dementia, amyotrophic lateral sclerosis, and other ... is perhaps more concerning, is that even when ...
(Date:7/13/2014)... identifies a novel genetic and molecular pathway ... opening up potential new therapeutic strategies for an ... is a chronic inflammatory disorder of the esophagus. ... certain foods and an over-accumulation in the esophagus ... the body,s immune system). EoE can cause a ...
(Date:7/13/2014)... July 13, 2014 The North American water ... in 2013 to $5,450 million by 2018, at a CAGR ... market is expanding at a rapid pace in North America. ... tightening laws on water & wastewater storage and collection, and ... The market is expanding at a healthy rate in Canada, ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 Athletes ... longer recovery period from concussions, according to research presented ... ( AOSSM ) Annual Meeting. The research marks the ... concussion based on the known physical events that occur ... patients with a long allele in the (GT)n genotype ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... Programs for Eating Disorders,( http://www.remudaranch.com ), the nation,s ... surround the nation,s obsession,with dieting. As the dieting ... Americans continue to lose and gain weight in ... cycling may elevate blood pressure,reduce good cholesterol, deplete ...
... Medical Technologies,Inc., an innovator of endovascular treatments for ... another patent for its,Pathway PV(TM) Atherectomy System. The ... related to Pathway Medical,s innovative,atherectomy system, which is ... the legs. Pathway Medical has a total of ...
... women to enjoy casual sex just as men always had. ... the UK, the negative feelings reported by women after one-night ... sexual encounters. Her findings (1) are published online in ... , Men are more likely to reproduce and therefore to ...
... hurt. It was like [their father] had met some gal ... she wanted all his money. I felt they didn,t give ... still hurts.", --Remarried wife of 12 years, caring for husband ... Mich.---Late-life remarriage complicates caring for an ailing spouse, according to ...
... June 25 Hologic, Inc.,(Nasdaq: HOLX ) today ... the waiting period under the Hart-Scott-Rodino,Antitrust Improvements Act of ... in connection with Hologic,s previously announced tender offer for,all ... Third Wave,Technologies, Inc. (Nasdaq: TWTI ). The early ...
... looking for qualified candidates and tens of thousands of jobs being created ... graduates and despite the layoff announcements that tend to shock the average ... ... number of available jobs in health care continued to rise through the ...
Cached Medicine News:Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 2Health News:Leading Eating Disorder Treatment Center Identifies Popular Diet Myths 3Health News:Was it good for you too? 2Health News:Late-life remarriage: Stepfamilies make caring more complex 2Health News:Hologic, Inc. Announces Grant of Early Termination of Antitrust Waiting Period for Third Wave Technologies, Inc. Tender Offer 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: May 2008 Employment Outlook for Biotech/Pharma/Health 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The Retinal Acuity Meter (RAM) is the ... to accurately predict RETINAL ACUITY in eyes with ... hand-held, battery operated, and can test each eye ... Optics, Inc. and tested at Columbia University in ...
... The Hoffmann® II Hybrid External Fixation ... next generation in hybrid fixation. It ... surgeons and is designed to offer ... exclusive patented Hoffmann® snap-fit technology. , ...
... add individual components for individual indications. XCaliber ... Made of an innovative composite plastic material, ... much lighter. This means it's easier to ... for the patient. ,Come pre-assembled, packaged sterile, ...
Medicine Products: